The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer’s disease diagnostic revolution
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Widespread clinical use of PET and CSF has been hampered by high costs, reliance on expensive equipment and specially trained personnel, and perceived invasiveness.
“However, although safe, the widespread clinical use of PET and CSF has been hampered by high costs, reliance on expensive equipment and specially trained personnel and perceived invasiveness11.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [11]
In “Roles of molecular imaging, BBBM, and CSF biomarkers” (page not supplied), the paper says PET’s high cost and need for specialized equipment and personnel limit its clinical use. The same section says lumbar puncture requires specialized personnel and can be perceived as invasive. It does not present high cost or expensive equipment as barriers to CSF testing; instead, it says CSF biomarkers cost less than PET and are typically reimbursed. (LLM, conf=0.85)
Experimental — accuracy not yet measuredThe presence of Aβ pathology can be determined by PET or CSF assays measuring Aβ42/40, p-tau or total tau.
“The presence of Aβ pathology can be determined by positron emission tomography (PET), which visualizes Aβ deposition in the brain, or cerebrospinal fluid (CSF) assays, which measure CSF levels of Aβ42 as a ratio with Aβ40, phosphorylated tau (p-tau) or total tau4,9–11.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · see citing works
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · see citing works
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045 · see citing works
Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764 · see citing works
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651 · see citing works
Hansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607 · see citing works
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain · doi:10.1093/brain/awac333 · Cited by 522 · see citing works
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3180 · Cited by 494 · see citing works
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266 · see citing works
Self-citationCSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease
Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180 · see citing works
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies
Bellomo, G., Luca, C. M. G. D., Paoletti, F. P., Gaetani, L., Moda, F., & Parnetti, L. (2022) · Neurology · doi:10.1212/wnl.0000000000200878 · Cited by 160 · see citing works
Angioni, D., Delrieu, J., Hansson, O., Fillit, H. M., Aisen, P. S. S., Cummings, J. L., Sims, J. R., Braunstein, J. B., Sabbagh, M. N., Bittner, T., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.85 · Cited by 125 · see citing works
Self-citationCSF tau microtubule-binding region identifies pathological changes in primary tauopathies
Horie, K., Barthélemy, N. R., Spina, S., VandeVrede, L. A., He, Y., Paterson, R. W., Wright, B. A., Day, G. S., Davis, A. A., Karch, C. M. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02075-9 · Cited by 96 · see citing works
Karikari, T. K. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215730 · Cited by 37 · see citing works
Fluid Biomarkers in Dementia Diagnosis
Schindler, S. E. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001083 · Cited by 31 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448 · see citing works
Self-citationBlood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Schindler, S. E., Smith, R., Ossenkoppele, R., Calling, S., West, T., Monane, M., Verghese, P. B., et al. (2024) · JAMA · doi:10.1001/jama.2024.13855 · Cited by 416 · see citing works
Self-citationSchindler, S. E., Galasko, D. R., Pereira, A. C., Rabinovici, G. D., Salloway, S., Suárez‐Calvet, M., Khachaturian, A. S., Mielke, M. M., Udeh‐Momoh, C. T., Weiss, J. O., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00977-5 · Cited by 311 · see citing works
Self-citationHead‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
(2024) · doi:10.1002/alz.14315 · Cited by 199 · see citing works
Self-citationRecommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
Mielke, M. M., Anderson, M., Ashford, J. W., Jeromin, A., Lin, P., Rosen, A. C., Tyrone, J., VandeVrede, L. A., Willis, D. R., Hansson, O., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14184 · Cited by 125 · see citing works
Self-citationAtri, A., Dickerson, B. C., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14333 · Cited by 77 · see citing works
Self-citationDickerson, B. C., Atri, A., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14337 · Cited by 59 · see citing works
Self-citationConsiderations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
Mielke, M. M., Anderson, M., Ashford, J. W., Jeromin, A., Lin, P., Rosen, A. C., Tyrone, J., VandeVrede, L. A., Willis, D. R., Hansson, O., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14150 · Cited by 45 · see citing works
Self-citationTiming of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks
Milà‐Alomà, M., Tosun, D., Schindler, S. E., Hausle, I., Petersen, K. K., Li, Y., Dage, J. L., Du‐Cuny, L., Saad, Z. S., Saef, B. A., et al. (2025) · Annals of Neurology · doi:10.1002/ana.27285 · Cited by 44 · see citing works
Self-citationClinical use of biomarkers in the era of Alzheimer's disease treatments
VandeVrede, L. A., & Schindler, S. E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14201 · Cited by 36 · see citing works
Self-citationBaseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals
Xiong, C., Luo, J. R., Wolk, D. A., Shaw, L. M. J., Roberson, E. D., Murchison, C., Henson, R. L., Benzinger, T. L. S., Bui, Q. V. P., Agboola, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49859-w · Cited by 24 · see citing works
Self-citationBonomi, S., Lu, R., Schindler, S. E., Bui, Q. V. P., Lah, J. J., Wolk, D. A., Gleason, C. E., Sperling, R. A., Roberson, E. D., Levey, A. I., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26838 · Cited by 22 · see citing works
Self-citationAlzheimer's Disease Diagnosis in the Preclinical Stage: Normal Aging or Dementia
Marvi, F., Chen, Y.-H., & Sawan, M. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2024.3376835 · Cited by 23 · see citing works
Kobayashi, G., Hirata, K., Ono, M., Kasuga, K., & Takado, Y. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1736297 · Cited by 21 · see citing works
Paving the way for Alzheimer's disease blood‐based biomarkers in primary care
Erickson, C. M., Largent, E. A., & O’Brien, K. S. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14203 · Cited by 15 · see citing works
Towards pharmacological prevention of Alzheimer disease
Llibre‐Guerra, J. J., McDade, E., Schindler, S. E., Clifford, D. B., Supnet, C. B., Atri, A., & Bateman, R. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01154-y · Cited by 15 · see citing works
Self-citationUniversal Artificial Urinary Biomarker Probe Enabled by an Aptamer–DNAzyme–Nanozyme Construct
Xiao, Y., Wong, J. H., Gao, N., Barron, A. M., Stanley, C. V., Than, A., Zheng, L., Ling, T., Li, D., & Chen, P. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c02356 · Cited by 15 · see citing works
Evidence gap in blood biomarkers for Alzheimer’s disease
van Gool, W. A., Siebrand, J. A. F., Brayne, C., Larson, E. B., & Richard, E. (2025) · BMJ · doi:10.1136/bmj-2025-084781 · Cited by 14 · see citing works
Blood-Based Biomarkers for Alzheimer Disease—Ready for Primary Care?
VandeVrede, L. A., & Rabinovici, G. D. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2801 · Cited by 14 · see citing works
Bonomi, S., Gupta, M. R., & Schindler, S. E. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13473 · Cited by 12 · see citing works
Self-citationXiong, C., Schindler, S. E., Luo, J. R., Morris, J. C., Bateman, R. J., Holtzman, D. M., Cruchaga, C., Babulal, G. M., Henson, R. L., Benzinger, T. L. S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3783571/v1 · Cited by 10 · see citing works
Self-citationHeiskanen, M. A., Mykkänen, J., Pahkala, K., Juonala, M., Kähönen, M. A. P., Lehtimäki, T. J., Laitinen, T. P., Jokinen, E., Tossavainen, P. H., Linko-Parvinen, A., et al. (2025) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2025.100717 · Cited by 9 · see citing works
Arranz, J., Ferrer, R., Zhu, N., Rubio‐Guerra, S., Rodríguez‐Baz, Í., Arriola‐Infante, J. E., Maure‐Blesa, L., Castro, J. G., Selma‐González, J., Carmona‐Iragui, M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01779-7 · Cited by 8 · see citing works
Unexpected Low Rate of Amyloid‐β Pathology in Multiple Sclerosis Patients
Brier, M. R., Schindler, S. E., Salter, A. R., Perantie, D. C., Shelley, N., Judge, B., Keefe, S., Kirmess, K. M., Verghese, P. B., Yarasheski, K. E., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27027 · Cited by 8 · see citing works
Self-citationPredicting continuous amyloid PET values with CSF tau phosphorylation occupancies
Wisch, J. K., Gordon, B. A., Barthélemy, N. R., Horie, K., Henson, R. L., He, Y., Flores, S. E., Benzinger, T. L. S., Morris, J. C., Bateman, R. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14132 · Cited by 8 · see citing works
Self-citationSharma, A., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150047 · Cited by 6 · see citing works
Chen, Y., Su, Y., Su, Y., Chen, K., Atri, A., Caselli, R. J., Reiman, E. M., Wang, Y., & Initiative, T. A. D. N. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231162 · Cited by 6 · see citing works
Self-citationUnlocking ocular biomarkers for early detection of Alzheimer's disease
Dave, N., Lee, M., Pavlou, H., Im, O., Goh, K., Ulin, S., Malzbender, K., Shobin, E., & Sukumar, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14567 · Cited by 6 · see citing works
Wang, S., Liu, D., Li, H., Jia, X., Zhou, H., Yu, W., Li, T., Pan, L., Chen, B., Wang, Y., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1554805 · Cited by 5 · see citing works
Yan, J. T., Dillon, A., Meng, T., Ramesh, V., Sabbagh, M. N., Sharma, V., & Roth, S. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70156 · Cited by 3 · see citing works
Balogun, W. G., Zeng, X., Triana‐Baltzer, G., Saeed, A., Aigbogun, H. E., Gogola, A., Lopresti, B. J., Villemagne, V. L., Ganguli, M., Kolb, H. C., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70916 · Cited by 3 · see citing works
Finney, C. A., Initiative, A. D. N., & Shvetcov, A. (2026) · npj Aging · doi:10.1038/s41514-026-00390-w · Cited by 2 · see citing works
Suleman, M. U., Mursaleen, M., Khalil, U., Khan, S. A., Saboor, A., Hussnain, M. A., Zahir, M., Khan, U. A., Rehman, D. U., & Tabassum, S. N. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004505 · Cited by 2 · see citing works
Prominent Perspective on Existing Biological Hallmarks of Alzheimer’s Disease
Singh, N., Sharma, S., Ghosh, K. K., Gupta, B., & Kuča, K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266292514240404040341 · Cited by 2 · see citing works
Li, Y., Gu, W., Li, Y., Zhao, Z., Liu, T., Ke, P., Lin, H., Wang, Q., Huang, X., & Zhang, Q. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.167096 · Cited by 1 · see citing works
Target product profiles for treatments to delay or prevent symptomatic Alzheimer’s disease
Cummings, J. L., Agadjanyan, M. G., Barry, M., Corey, L., Doody, R., Hendrix, S. B., Mattke, S., Mattsson, N., McDade, E., Menetski, J. P., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04305-w · Cited by 1 · see citing works
Blood-based biomarker analysis of Alzheimer’s disease by proteomics profiling
Velmurugan, G., Upadhyay, R., Sevanan, M., & Chinnathambi, S. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.03.003 · Cited by 1 · see citing works
Plasma biomarker trajectories across Alzheimer’s clinical onset: a 17-year prospective study
Xie, S., Liang, Y., Pang, Y., Li, Y., Cao, S., Li, Y., Wang, Q., Moghekar, A., Albert, M., Jia, J., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02045-0 · Cited by 1 · see citing works
Poli, M., Bonomi, C. G., Donna, M. G. D., Barberis, I., Ginevra, E., Nuccetelli, M., Bernardini, S., Centonze, D., Martorana, A., & Motta, C. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13833-x · Cited by 1 · see citing works
Human whole-epigenome modelling for clinical applications with PleiadesPreprint
Niki, P., Nalmpantis, C., Ganbat, J.-O., Byrne, D., Kathail, P., Fang, C., Wong, A., Karailiev, A., Babikir, H. A., Jhutty, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.16.665231 · Cited by 1 · see citing works
Dadgostar, M., Hanford, L. C., Tavakoli, M., Arnold, S. E., Salat, D. H., Sitnikova, T., Webb, P. K., Green, J. R., Liu, H., Richburg, B. D., et al. (2026) · medRxiv · doi:10.64898/2026.01.15.26344226 · Cited by 1 · see citing works
Wei, X., Gao, N., Xu, M., Rezaeitalesh, M., Mu, N., Lyu, Z., Ngala, M., Jiang, J., & Chang, X. (2023) · International Journal of Online and Biomedical Engineering (iJOE) · doi:10.3991/ijoe.v19i17.44173
Affeldt, A. M. (2024) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-024-02361-w
Neuropsychologie du vieillissement normal et des syndromes démentiels
Gil, R. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-78570-2.00023-x
Wang, S., Liu, D., Li, H., Jia, X., Zhou, H., Yu, W., Li, T., Pan, L., Chen, B., Wang, Y., et al. (2024) · medRxiv · doi:10.1101/2024.12.25.24319645
Musto, H., Stamate, D., Reeves, D., Morgan, C., Hutanu, R., Mavromati, K., Cadar, D., & Stahl, D. R. (2025) · IFIP advances in information and communication technology · doi:10.1007/978-3-031-96235-6_18
Bailey-Taylor, M. J., Morrow, P., Hendrix, J., Galluzzi, K. E., & Sharafsaleh, G. (2026) · Clinical Interventions in Aging · doi:10.2147/cia.s585263
Juday, T. R., Holub, A., Mattke, S., Betts, K. A., Kitchen, S. A., Liu, H., Frech, F. H., & Khachaturian, A. S. (2026) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175261433309
Syed, A., Mirza, A., & Bhatti, A. (2026) · Journal of Community Medicine and Health Solutions · doi:10.29328/journal.jcmhs.1001078
- Authors
- Schindler, S. E., & Atri, A.
- Affiliations
- Washington University in St. Louis (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Schindler, Suzanne E.
- Venue
- Nature Aging
- Published
- 2023-05-18
- Volume
- 3
- Issue
- 5
- Pages
- 460-462
- ISSN
- 2662-8465 (ISSN-L)
- PMC
- PMC10720501
- OpenAlex
- W4377029844
- Cited by
- 49
- References
- 15
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 21 · 2023: 3
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Aging (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG070941, 1P30AG072980)
- Foundation for Barnes-Jewish Hospital
- Arizona Department of Health Services (CTR040636)
- Foundation for the National Institutes of Health
- WUSTL | Washington University School of Medicine in St. Louis
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, blood-based biomarkers, molecular imaging, dementia diagnosis, diagnosis
- MeSH terms
- Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
